Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
beta 1 integrin shRNA
- Development stage
- Preclinical
- Lead developer
- San Diego VA Health Care System
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
Beta 1 integrin shRNA is an RNA interference (RNAi) therapeutic candidate designed to silence the expression of the beta 1 integrin subunit (ITGB1). Integrins are a family of heterodimeric transmembrane receptors that mediate cell-extracellular matrix (ECM) interactions, which are often upregulated in pancreatic cancer and contribute to tumor progression, migration, and metastasis. This specific shRNA is delivered via a lentiviral vector to target ITGB1 mRNA, leading to a significant reduction in protein expression. Preclinical research has shown that knockdown of the beta 1 integrin subunit inhibits cell adhesion, proliferation, and migration on various ECM proteins such as collagen and fibronectin. In orthotopic mouse models of pancreatic cancer, treatment with beta 1 integrin shRNA has been shown to significantly inhibit tumor growth and completely prevent metastasis and ascites formation, highlighting its potential as a targeted therapy for aggressive solid tumors.
- Other names
- ITGB1 shRNAITGB-1 shRNAITGB 1 shRNAintegrin beta-1 shRNAbeta 1 integrin knockdownbeta1 integrin knockdownbeta-1 integrin knockdown
02
Targets
ITGB1 (Integrin beta-1)
Beyond the preview
Go deeper on beta 1 integrin shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on beta 1 integrin shRNA.